Kedudukan dalam Saham
#5577
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the... Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Harga Saham
$36.98
Disegerakkan terakhir: 2026-08-26
Perubahan (1 hari)
-0.67%
Perubahan (1 tahun)
55.51%
Perdagangan Pharvaris N.V. (PHVS)
Harga PHVS dengan permodalan pasaran b
Modal pasaran bagi Pharvaris N.V.(PHVS)
Modal Pasaran: $2.58B
Sehingga August 2026, Pharvaris N.V. mempunyai modal pasaran sebanyak $2.58B. Ini menjadikan Pharvaris N.V. syarikat ke-5577th paling bernilai di dunia mengikut data kami. Kapitalisasi pasaran ialah nilai keseluruhan saham syarikat tersenarai yang berada dalam edaran dan lazimnya digunakan untuk menilai nilai syarikat tersebut.
Sejarah modal pasaran Pharvaris N.V. dari 2021 hingga 2026
PHVS berbanding dengan 5 teratas yang paling popular stocks
| Harga PHVS |
|
Aset B |
Pasaran B |
Hasilnya |
|
|
|
|
$5.088T
|
+196,787.13%
|
|
|
|
|
$4.629T
|
+179,033.69%
|
|
|
|
|
$4.118T
|
+159,240.09%
|
|
|
|
|
$3.687T
|
+142,566.18%
|
|
|
|
|
$2.800T
|
+108,238.93%
|
